Payment overview · 2025
General Payments
$80.60
5 reported records · 4 companies
Healthcare provider profile · identity verified
James Barton Vogt, MD
Allopathic & Osteopathic Physicians|Family Medicine · SCOTTSDALE, AZ · NPI 1740332352
Verified facts
What the public records show
CMS Open Payments records show James Barton Vogt, MD received $80.60 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.71 | 43.1% | 2 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $15.81 | 19.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.68 | 19.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.40 | 17.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $80.60 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 96 |
| Trazodone Hcl | Trazodone Hcl | 296 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 78 |
| Losartan Potassium | Losartan Potassium | 244 | 67 |
| Gabapentin | Gabapentin | 231 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 49 |
| Lisinopril | Lisinopril | 182 | 56 |
| Metformin Hcl | Metformin Hcl | 153 | 45 |
| Omeprazole | Omeprazole | 131 | 43 |
| Alprazolam | Alprazolam | 111 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 34 |
| Allopurinol | Allopurinol | 97 | 26 |
| Famotidine | Famotidine | 97 | 25 |
| Montelukast Sodium | Montelukast Sodium | 94 | 32 |
| Sertraline Hcl | Sertraline Hcl | 94 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 24 |
| Simvastatin | Simvastatin | 83 | 25 |
| Azithromycin | Azithromycin | 81 | 60 |
| Eliquis | Apixaban | 78 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 22 |
| Furosemide | Furosemide | 75 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 17 |
| Lorazepam | Lorazepam | 75 | 16 |
| Mirtazapine | Mirtazapine | 74 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 14 |
| Valsartan | Valsartan | 65 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 18 |
| Tramadol Hcl | Tramadol Hcl | 62 | 16 |
| Bupropion Hcl | Bupropion Hcl | 59 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 18 |
| Clonazepam | Clonazepam | 57 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 11 |
| Ozempic | Semaglutide | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Finasteride | Finasteride | 40 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 18 |
| Diazepam | Diazepam | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Atenolol | Atenolol | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $80.60 · 5 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ArdeoGraft, LINZESS, PelloGraft, REPATHA, RenoGraft, SurGraft, SurMatrix | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error